Brief: Everest Medicines Says FY Loss Attributable Rmb1,008.7 Mln Versus Rmb5,658.2 Mln
29/03/2022 02:36
March 29 (Reuters) - Everest Medicines Ltd 1952.HK :
* FY LOSS ATTRIBUTABLE RMB1,008.7 MILLION VERSUS RMB5,658.2
MILLION
* FY REVENUE RMB54,000
Further company coverage: 1952.HK
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region